0.61
-1.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Creative Medical Technology Holdings
From its filings with the US Securities and Exchange Commission
Creative Medical Technology Holdings is based in Phoenix, Arizona and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CELZ. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $6,000 and a net loss of $6.0m. At that date it held total assets of $7.8m and shareholders' equity of $7.5m.
Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities.
In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz™ platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties (or “supercharges” them) providing them with the ability to treat multiple indications. We have validated this ability through the third-party studies described below that were independently conducted on selected human donor patient cells for accuracy and reproducibility.
Quoted from its 10-K, filed 20 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 1 May 2009
- Employees
- 4
- Website
- creativemedicaltechnology.com ↗
- Head office
- 211 E. OSBORN RD., PHOENIX, AZ, 85012
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Timothy WarbingtonPresident, Chief Executive Officer, Director, since 2016$586,500
- Mr. Donald DickersonChief Financial Officer, Senior Vice President, Director, since 2016$525,000
- Mr. Michael FingerIndependent Director$80,000
- Ms. Susan SnowIndependent Director$120,000
- Mr. Bruce UrdangIndependent Director$100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical-stage biotechnology company focused on stem cell treatments for erectile dysfunction and stroke.
- Subsidiary CMT conducts testing for erectile dysfunction treatment and plans to market Caverstem kits.
- Company employs 4 employees with a clinical-stage focus on stem cell applications.
Weaknesses
- Headquartered in Phoenix, Arizona with only 4 employees.
- Company went public in 2009 with no full-time employees at the time of listing.
- CMT focuses on completing testing for erectile dysfunction treatment without current commercialization.
Opportunities
- Stem cell research applications for male and female sexual dysfunction and infertility treatments.
- Expansion of Caverstem kits for erectile dysfunction under physician use in outpatient settings.
- Testing and potential marketing of licensed stem cell products for infertility technology.
Threats
- No full-time employees at the time of IPO in 2009 with only 4 employees currently.
- Stem cell research faces regulatory challenges in medical applications.
- CMT's focus on testing without commercialization may delay market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.